Propanc Biopharma, Inc.: Form 10-Q for the period ended Dec 31, 2021
Filed with the SEC on Feb 14, 2022 and accepted by EDGAR at Feb 14, 2022, 13:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2021-10-01 to 2021-12-31 | $50.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-07-01 to 2021-12-31 | $97.3k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-10-01 to 2021-12-31 | −$403.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-07-01 to 2021-12-31 | −$889.5k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-10-01 to 2021-12-31 | $177.9k | us-gaap:InterestExpense |
| Interest expense | 6 months2021-07-01 to 2021-12-31 | $287.8k | us-gaap:InterestExpense |
| Income tax | 3 months2021-10-01 to 2021-12-31 | −$55.5k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2021-07-01 to 2021-12-31 | −$55.5k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-10-01 to 2021-12-31 | −$800.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-07-01 to 2021-12-31 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-10-01 to 2021-12-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2021-07-01 to 2021-12-31 | −$0.04 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2021-07-01 to 2021-12-31 | −$711.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2021-12-31 | $73.6k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $84.9k | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $110.2k | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $3.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $3.0m | us-gaap:Liabilities |
| Long-term debt | At period end2021-12-31 | $972.7k | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2021-12-31 | −$2.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-22-004382. Last ingested by Listed: Oct 29, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.